NEW YORK CITY, NY / ACCESS Newswire / October 22, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST.Aquestive Investigation DetailsThe investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in corporate wrongdoing.What's Next for Aquestive Investors?If you are aware of any facts relating to this investigation or purchased Aquestive shares, you can assist this investigation by visiting the firm's site: bgandg.com/AQST. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911No Cost to Aquestive InvestorsWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.Why Bronstein, Gewirtz & Grossman, LLC for Aquestive Securities Investigation?Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide."Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.Follow us for updates on LinkedIn, X, Facebook, or Instagram.Contact InfoPeretz Bronstein, Esq. or Nathan MillerBronstein, Gewirtz & Grossman, LLC917-590-0911 | info@bgandg.comAttorney advertising.Prior results do not guarantee similar outcomes.SOURCE: Bronstein, Gewirtz & Grossman, LLCView the original press release on ACCESS Newswire

COMTEX_1001550501/2457/2026-10-23T02:32:33